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Faced with the end stage of heart disease, the current treatments onlyslow worseningof heart failure. Stem cells have the potential
of self-renewal and diﬀerentiation. It is expected to replace and repair damaged myocardium. But many clinical trials have shown
thatthe stem cell therapy of heart failure is modest ornot eﬀective. The possible causes forthe limited eﬀects of stem cell in curing
heart failure are the stem cells which have been transplanted into the ischemic heart muscle may suﬀer low survival rate, aﬀected
by inﬂammatory molecules, proapoptotic factor, and lack of nutrients and oxygen, and then the stem cells which home and have
been completely transplanted to the site of myocardial infarction become very small. Therefore, through preconditioning of stem
cells and appropriate choice of genes for mesenchymal stem cell modiﬁcation to improve the survival rate of stem cells, ability in
homing and promoting angiogenesis may become the newly eﬀective strategies for the application of stem cells therapy in heart
failure.
1.Introduction
With the changes in lifestyle and aging of population, the
morbidityof hypertension, coronary heart disease, andother
common cardiovascular disease has shown a continuous ris-
ingtendency.Astheendstageofcardiovascular disease,heart
failure suﬀers high morbidity and poor prognosis. Heart
failure was mentioned on 277193 death certiﬁcates and was
the underlying cause in 56 565 of those deaths in the United
States in 2007 [1, 2]. According to a random sampling
survey to 15,518 residents aging from 35 to 74 in China in
2003, the prevalence of heart failure was 0.9%. It was lower
than developed countries. However, the total prevalence
was still up to 4,000,000, and the incidence was increasing
ceaselessly [3]. Current drug treatment can only improve
symptoms without preventing the ventricular remodeling
and the deterioration of progressive heart function. Heart
transplantation is an eﬀectivemeans of treating patients with
heart failure. But the vast majority of patients are restricted
by the age, the donor, surgical complications, medical costs,
and so forth.
Stem cells are the origin cells of various mature cells.
They have the potential of self-renewal and diﬀerentiation.
Either immediately after isolation orafter expansion in vitro,
stem cells are transplanted into a speciﬁc region of the heart,
and ultimately replace, repair the myocardial necrosis or
pathological cells; then the aim of curing heart failure can
be achieved and it has brought a bright prospect for the
treatment of heart failure. Although the basic research on
the diﬀerentiation of stem cell transplantation has not yet
achieved consistent results, many clinical trials regarding the
stem cell transplantation for acute and chronic heart failure
have been carried out [4]. The results suggest that stem
cells therapy improve the clinical symptoms modestly, but
almost have no eﬀect in preventing ventricular remodeling
and long-term prognosis.
2.ClinicalExperience
Currently, the main types of stem cells used for clinical treat-
ment include bone marrow-derived cells (BMCs), adipose-
derived stem cells (ADSCs), cardiac stem cells (CSCs),
peripheral blood derived cells, embryonic stem cells (ES),
and induced pluripotent stem cells (Figure 1). Autologous
skeletal myoblast is one of the stem cells which have been2 Stem Cells International
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Figure 1: The cell types used in heart repair.
ﬁrstly used in myocardial regeneration. It can counteract
ischemia and has the ability of regeneration after damage.
However, skeletal myoblasts cannot form an eﬀective elec-
trical coupling synchronization with the living myocardial
cells and may lead to malignant arrhythmia [5]. It has been
shown that ES transplantation can improve cardiac contrac-
tile function and still have proliferative capacity. However,
ethical debate of embryonic stem cells, immune rejection,
and the risk of tumorigenicity still hinder its application.
2.1. Bone Marrow-Derived Cells. BMC is currently the most
widelyusedcellsinclinicaltrials(Table 1).Itmainly contains
mesenchymal stem cells (MSCs), hematopoietic stem cells,
border cells, endothelial progenitor cells, and so forth.
Although, the acquisition of BMC induces pain and the
number of BMCs decreases dramatically with age, it is
relatively simple to separate and large numbers of cells
can be obtained without the need for ex vivo expansion.
It provides initial cells with many mixed components and
mutidiﬀerentiation potential. Furthermore, transplantation
of autologous cells avoids immune rejection and ethical
disputes caused by embryonic stem cells transplantation.
REPAIR-AMI [6] multicenter randomized controlled trial
included204 patientswith acutemyocardial infarction. After
3∼7 days’ reperfusion therapy, they received the autologous
bone marrow-derived mononuclear cells (BMMNCs) intra-
coronary or placebo (medium) treatment. 4 months later,
the treatment group left ventricular ejection fraction (LVEF)
improved slightly. Compared with the control group, there
were statistically signiﬁcant diﬀerences. However, in one-
year-followup, the cardiac indicators associated with remod-
eling had no signiﬁcant changes. Subgroup analysis showed
that only patients with large myocardial infarction had
amarkedeﬀect.EuropeanSTAR-heart[7]examinedthestem
cells treatment for chronic heart failure. 391 patients with
chronic heart failure patients due to ischemic heart disease
(myocardial infarction) were included,diagnostic criteria for
LVEF
￿ 35%. BMMNCs directly infused to related artery
infarction through angioplasty balloon catheter. Eﬀects on
the patients were evaluated after treatment of 3 months to
5years.LVEF,cardiacindex,exercisecapacity,oxygenuptake,
and left ventricular contractility had improved signiﬁcantly.
In addition, in the ﬁrst assessment after 3-month treatment
the beneﬁcial eﬀects observed lasted to 12 months and 60
months, while there was a phenomenon of deterioration of
left ventricular function in the control group at the same
time. Compared with the control group, long-term mortality
of patients treated with stem cells signiﬁcantly decreased.
Although the results of many experiments show that
BMC transplantation can improve LVEF (compared with
the control group, only about 3%), there are no obvious
long-term eﬀects [17]. Recent meta-analysis of a series of
published clinical trials before 2009 also found that although
coronary artery transplanted stem cells can signiﬁcantly
reduce left ventricular end systolic volume in patients with
acutemyocardialinfarction,theyhavenosigniﬁcanteﬀecton
leftventricularend-diastolicvolume[19].Intherandomized
controlledBOOSTtrial[12],patientswithSTsegmenteleva-
tion after acute myocardial infarction received an intracoro-
nary BMC infusion. Resultsshowed that LVEF had improved
after 6 months, but there were no signiﬁcant diﬀerences
compared with the control group after 18 months. In 5-year
followup, all indicators did not ﬁnd diﬀerenceswith the con-
trol group. However, according to the current trials, the rate
ofadverse eﬀectwith autologousBMC transplantation is rel-
atively low, and compared with conventional treatment, theStem Cells International 3
Table 1: Randomized controlled bone marrow-derived cell trials in myocardial infarction.
Studies Mean age
(years)
Patients
randomized
(patients
followup)
LVEF
baseline (%)
Followup
(month) Dose Assessment method Outcome
Chen et al.
(2004) [8] 58 69 (69) 49 6 6 ×10
10 Echo EF increased 18%
REPAIR-AMI
(2006) [9] 56 204 (187) 47.6 12 2.4 ×10
8 Angiography EF increased
2.5%
ASTAMI (2006)
[10] 57.4 100 (100) 46.3 6 8.7 × 10
7 Echo/SPECT/MRI No eﬀect
TCT-STAMI
(2006) [11] 58.5 20 (20) 56 6 4 ×10
7 Echo/SPECT EF ↑ 6.7%
BOOST (2009)
[12] 56.3 60 (60) 50.7 60 2.5 ×10
9 MRI No eﬀect
Janssens et al.
(2006) [13] 58.7 67 (66) 47.7 4 1.7 ×108 MRI No eﬀect
Meluz´ ın et al.
(2006) [14] 55 66 (66) 41.7 3 108/107 SPECT/Echo
EF increased 3%
(108). No eﬀect
(107)
Huikuri et al.
(2008) [15] 59.5 80 (77) 60.5 6 3.6 ×10
8 Echo/Angiography
EF increased 4%
(Echo)/7.1%
(angiography)
Plewka et al.
(2009) [16] 56 60 (56) 37 6 1.44 ×10
8 Echo EF increased 10%
REGENT (2009)
[17] 57 200 (199) 37 6
1.78 ×10
8/
1.9 ×106
(sorted)
MRI EF increased 3%
W¨ ohrle et al.
(2010) [18] 61 42 (42) 54 6 3.81 ×10
8 MRI EF increased
5.7%
STAR-heart [7] 59.5 391 (391) 32.83 60 6.6 ×10
7 Angiography EF increased
6.2%
All studies demonstrated satisfactory patient matching. EF: ejection fraction; Echo: echocardiography; SPECT: single-photon-emission computed tomogra-
phy; MRI: magnetic resonance imaging.
incidence of malignant arrhythmias, restenosis did not sig-
niﬁcantly elevate. The safety of BMC transplantation has
been initially veriﬁed.
Clinical studies on intracoronary BMC infusion in pa-
tients with myocardial infarction revealed mixed results,
partly because of marked heterogeneity between trials [12].
The preclinicalstudies were performed in young healthy ani-
malswith a single coronaryocclusion.The clinicaltrials were
performed in old patients with extensive comorbidities. The
numbers and proliferation of stem cells decline in elderly
patients. This may be the reason that the clinical trials
were not as beneﬁcial as the animal studies. But a meta-
analysis suggests that BMC therapy is likely more eﬀective
in ageing and diabetic individuals [20]. A speculation is that
the patients who are ageing, postmenopausal female, or
diabetic are likely to suﬀer from impaired endothelium and
to have inadequate physiological angiogenesis response to
ischemia, therefore tend to gain beneﬁcial eﬀects from the
supplementation of BMC. Many current clinical trials are
not double-blind studies, and there could be a “placebo
eﬀect”. The long-term eﬀectiveness of BMC treatment of
heart failure needs the evidence of large-scale double-blind
randomized controlled trials.
2.2. Cardiac Stem Cells. Many kinds of CSCs which were
taken from adult heart tissue can be isolated and identiﬁed
including c-kit+ cells and Sca-1+ cells [21]. Regardless of
t h eg e n d e ro ra g eo ft h ep a t i e n t ,o ro fd i a b e t e s ,D a v i d
et al. [22] isolate in all of them a pool of functional
CSCs. Although less so in older or diabetic patients, they
found that cells had long telomeres, or “caps,” on their
chromosomal ends indicating that expanded CSCs retained
a signiﬁcant growth reserve. CSCs can diﬀerentiate into
three kinds of major heart cell precursors: myocardial cells,
smooth muscle cells and epithelial cells [23]. Although
isolation of these cells requires access to cardiac tissue,
CSCs have been successfully isolated from right ventricular
endomyocardial biopsy [24], a technique that could be used
clinically. Some Phase I clinical trials are being conducted to
observe the safety and feasibility of using CSCs in patients
(http://www.clinicaltrials.org/NCT00474461).
2.3. Induced Pluripotent Stem Cells. In 2006, Takahashi and
Yamanaka [25] reported the ﬁrst successful reprogramming
by delivering four stem cell-related genes (Oct3/4, Sox2,
Klf4, c-Myc) into skin ﬁbroblasts. The adult cells conversed
into an ES-like characteristic of pluripotent stem cells,4 Stem Cells International
called induced pluripotent stem cells (iPSs). iPSs avoid
a moral controversy, and can be patient-speciﬁc stem
cells. Human iPSs have been implanted in mouse models
of myocardial infarction, and it was indicated that they
regenerated myocardium, smooth muscle, and endothelial
tissue, restoring postischemic contractility performance
and electric stability [26]. As with ES, iPSs-derived cells
may be contaminated with potentially tumorigenic cells.
Ieda et al. [27] reported that a combination of three
developmental transcription factors rapidly and eﬃciently
reprogrammed postnatal cardiac or dermal ﬁbroblasts
directly into functional cardiomyocytes. Reprogramming of
endogenous or explanted adult cells might provide a source
of cardiomyocytes for regenerative approaches.
2.4.Adipose-Derived StemCells. Numerousstudieshavepro-
vided evidence that ADSCs contain a population of adult
multipotentmesenchymal stemcellsandendothelialprogen-
itorcells.Thesimilaritiesbetweenbonemarrow-derivedcells
and the ADSCs suggest the potential of the adipose tissue to
act as an alternative, and perhaps preferable, cell source for
repairing damaged myocardium. ADSCs are able to diﬀer-
entiate into multiple cell lineages including cardiomyocytes
[28]. ADSCs can eﬀectively improve LVEF in animal models
of acute and chronic myocardial infarction. According to a
small, ﬁrst-of-its-kind study [29], ADSCs can be safely ob-
tained and infused inside the hearts of patients following
an acute heart attack. ADSCs are emerging as a new source
of adult stem cells for cardiovascular repair. Certainly, more
clinical trials are needed to demonstrate the long-term eﬃ-
cacy and safety.
3.Mechanism of StemCellsTherapy
The stem cells including ES, CSCs, and iPSs can be diﬀeren-
tiated into cardiomyocytes after transplantation and restore
contractile function. They also can be diﬀerentiated into
endothelial cells and promote angiogenesis, turn part of the
damaged heart muscle alive, and limit scar expansion. Stem
cells including BMC and ADSCs transdiﬀerentiate into car-
diomyocytes in vivo, but no one has yet observed that MSCs
giverisetofullydiﬀerentiatedandfunctionalcardiomyocytes
in vivo [30, 31]. With the discovery of paracrine eﬀect of the
stemcell,many studieshaveconﬁrmed thatstem celltherapy
of heart failure depends on the mechanism, mainly in the
promotion of angiogenesis, against myocardial apoptosis,
immune regulation, and so on [32].
(1) The autocrine or paracrine growth factor such as
vascular endothelial growth factor (VEGF) promotes recon-
struction of myocardial vascular network [33]. VEGF can
increase permeabilityofcapillary wall, activate matrix metal-
loproteinase, and promote endothelial cell proliferation and
migration. It is one of the most important angiogenesis
factors. Research hasshown thatsustained highexpression of
VEGF, cooperated with the other angiogenesis factors (such
as bFGF), may promote the formation of smooth muscle
cells, participate in the “arteriogenesis” process, and improve
myocardial ischemia. Tang et al. [34] conﬁrmed capillary
proliferation in the areas of acute myocardial infarction and
surrounding area after stem cell transplantation.
(2) MSCs transplantation inhibits the activation of NF-
κB, attenuates the protein production of TNF-α and IL-
6, and increases anti-inﬂammatory cytokines IL-10 expres-
sion [35]. As proinﬂammatory cytokines, TNF-α and IL-
6h a v eat o x i ce ﬀect on myocardial cells, can inhibit the
cardiac contractile function, and induce apoptosis of car-
diomyocyte. In addition, they can regulate the expression
of monocyte chemoattractant protein, vascular endothelial
cellular adhesion molecule to chemotaxis of inﬂammatory
cells into myocardial tissue, increase myocardial tissue in-
ﬂammatory responses, and thus promote the progress of
ventricular remodeling after AMI [36]. As an anti-
inﬂammatory cytokine, IL-10 may be expressed by mono-
cytes, macrophages, cardiac cells, and so on. Through inhi-
bition of NF-κBa c t i v i t yt od e c r e a s eT N F - α and IL-6 expres-
sion, it can also inhibit the inﬂammatory response to some
degree [37].
(3) Cardiomyocyte hypertrophy and the extracellular
matrix depositionplay majorrolesin theremodeling ofnon-
infarcted myocardium. Pathologic increase in extracellular
collagen leads to interstitial ﬁbrosis, and although this can
be useful in limiting ventricular enlargement, it decreases
the compliance of ventricular wall and aﬀects heart function
[38]. MSCs transplantation improves cardiac function in
part through regulation of cardiac ﬁbroblasts proliferation
and transcriptional downregulation of types I and III col-
lagen syntheses [39] .T h i sm a yb eo n eo ft h em e c h a n i s m s
through which they inhibit the ventricular remodeling.
4.New Strategyand DirectionofStemCell
TherapyforHeartFailure
The stem cell transplantations for treatment of heart failure
havemodesteﬀectornoeﬀect.Inadditiontoproblemsinthe
best method of cell delivery, the treatment time, and patient
selection, an important common issue the transplantation
of stem cells faces is that the survival rate in the host is
very low. Because they are transplanted in an ischemia,
hypoxia, and proapoptotic niche, most stem cells cannot
survive after transplantation [40]. The results of real-time
PCR and TUNEL staining after the stem cells transplant
showed that more than 90% of the stem cells die within
24 hours after transplantation [41]. Another reason is the
amount of cells which migrate to regions of myocardial
infarction is too small. PET showed that only 1.3% to 2.6%
of the 18F-FDG-labeled stem cells which were intracoronary
injected migrated to the myocardium 2 hours after injection,
while the majority of the cells moved to the tissue outside
heart muscle,includingliver, spleen,lung,bladder, and brain
[42]. 20 hours later, the stem cells settled in the myocardium
are only about 1.49% [43]. In response to these problems,
there are some new strategies now.
5.Preconditioning
Inordertoimprovetheviabilityofstemcellsaftertransplan-
tation and counteract the hypoxia-induced apoptosis, it is anStem Cells International 5
eﬀective protection strategy to use various methods of pre-
conditioning of stem cells before transplanting the cells into
the damaged myocardium. Hypoxic preconditioning indi-
cates that the cell is cultivated under hypoxic conditions
before transplantation. Hypoxic preconditioning has been
foundtobeabletostartthePI3K/AKTsignalingpathwayand
enhance the stability of HIF-1 to increase the antiapoptotic
ability of MSCs [44]. Hypoxic preconditioning of peripheral
blood mononuclear cells increased the expression of various
genes related to antioxidant and survival signals remarkably
[45]. Hypoxic preconditioning also enhances the beneﬁt of
CSCstherapyfortreatment ofmyocardial infarction bySDF/
CXCR4 axis [46]. In addition to hypoxic preconditioning,
with some growth factors preconditioning on MSCs, it can
improve the ability of cell resistance to apoptosis, too. By
using stromal cell-derivedfactor-1 (SDF-1α)to precondition
MSCs, Pasha et al. [47] found that SDF-1 preconditioning
through SDF/CXCR4 activated multiple signaling pathways,
including the PI3K/AKT signaling pathway. Via using MSCs
with SDF-1 preconditioning for the treatment of myocardial
infarction inrats, it is found that the viability of MSCswhich
were transplanted signiﬁcantly increased, and they got
ab e t t e re ﬀect of myocardial repair. By Using diazoxide
to precondition MSCs, Afzal et al. found that diazoxide
preconditioning can enhance protective role of the MSCs
through the NF-κB signaling pathway [48].
6.CombinationDrug Therapy
After cell transplantation, administration of drugs combi-
nation therapy can also improve the viability of MSCs,
too. Statins used to reduce blood lipids in the past were
considered to have good protective action. Yang et al. [49]
used simvastatin to conduct the combination therapy, and
Xu et al. [50]conductedthecombinationtherapywithlovas-
tatin. They both got remarkable curative eﬀects. Then they
thought that simvastatin and lovastatin could have a cyto-
protective eﬀect by inhibiting the mitochondrial apoptotic
pathway to activate the signaling pathway of PI3K/Akt and
E R K 1 / 2 .I na d d i t i o n ,Z h a n ge ta l .[ 51]f o u n dt h a tC h i n e s e
herbs Berberine can inhibit the hypoxia-induced apoptosis
in vitro. The mechanism is also related to the inhibition of
the signaling pathway of mitochondrial apoptosis.
7.Gene ModiﬁedStemCells
7.1. Increase the Capacity of Antiapoptotic. The early apopto-
sis of the majority of stem cells after transplantation into the
ischemic heart imposes restrictions ontheirrepairfunctions.
Li et al. [52] applied anti-apoptotic gene Bcl-2 to modify
MSCs and found that the anti-apoptotic ability of modiﬁed
MSCs increased; they can also promote VEGF secretion
under the hypoxic condition; the number of surviving cells
after transplantation in vivo signiﬁcantly increased, and
improvement in cardiac function appeared signiﬁcantly. Lim
etal.[53]modiﬁedMSCswithAktandfoundthatAkt-MSCs
tolerated more about hypoxia-induced apoptosis. And after
hypoxia, extracellular signal regulated ERK activation, VEGF
expression increased, and survival of Akt-MSCs increased
after transplantation. Compared with MSCs transplantation
alone, it further repaired the damaged myocardium and
improved cardiac function. Through enhancing the MSCs’s
ability of antihypoxia, it can also play the role of increasing
the survival rate of the transplanted cells. Tang et al. [40]
modiﬁed MSCs with heme oxygenase -1 (HO-1), and
found tolerance of modiﬁed MSCs to hypoxia signiﬁcantly
increased, and the survival rate in the ischemic heart also
signiﬁcantly increased. Seven days after the transplantation,
survival rate of HO-1-modiﬁed MSCs was as 5 times as
that of the control group in vivo. With the modiﬁed MSCs
transplantation therapy of myocardial infarction, cardiac
function was further improved. These genes enhance the
viability of MSCs from such perspectives as anti-apoptotic,
promoting survivals, antioxidant protection, and so forth.
7.2. Promoting Angiogenesis. To promote angiogenesis eﬀec-
tively and improve myocardial blood ﬂow may be one of the
eﬀective ways of the treatment of ischemic heart disease.
Genes related to angiogenesis include VEGF, Ang-1, FGF-
2, IGF, and hepatocyte growth factor (HGF). Yang et al.
[54] used liposome-mediated method transfected pcDNA-
hVEGF to rat MSCs and used intramyocardial injections
method to inject the myocardium of the rat two weeks after
myocardial infarction. After four weeks, the results showed
that the cardiac function, infarct size, and angiogenesis of
the VEGF modiﬁed group were signiﬁcantly better than
the other groups, MSCs treatment group. Four weeks after
infarction, Yangetal.[55]transplantedHGF-modiﬁedMSCs
through the non-infarct-related coronary artery into pig
heart. The results showed a signiﬁcant increase in angiog-
enesis. Sun et al. [56] intramyocardially injected human
Ang1-modiﬁed MSCs (hAng1-MSCs) to treat rats acute my-
ocardial infarction. The results showed that hAng1-MSCs
could survive in the local and express hAng-1 mRNA and
protein. Vascular density of hAng1-MSCs and MSCs group
was signiﬁcantly higher than PBS control group, ventric-
ular remodeling and cardiac function were signiﬁcantly
improved. What is more, compared with MSCs, the increase
of angiogenesis and arteriogenesis and the decrease of the
infarct size and thickening of the left ventricular wall were
more signiﬁcant in hAng1-MSCs group.
7.3. Promote Migration. Most of the transplanted stem cells
cannot eﬀectively home in on the damaged heart; how to
improve the migration of stem cells is one of the research
directions in recent years. A series of signals caused by
necrosis after myocardial infarction leads to their own MSCs
mobilization into peripheralblood pool.The damagedtissue
expressed speciﬁc receptor or ligand, to guide corresponding
stem cells to move and adhere to the injury. SDF-1/CX2CR4
is currently known to promote the homing of MSCs in on
the injured tissue [57]. SDF-1/CXCR4 cannot only promote
the transplanted MSCs to migrate to the damaged tissue,
but also inhibit apoptosis of MSCs, increase the survival rate
and proliferation of MSCs [58], and promote the homing
eﬃciency of MSCs from many aspects. 24 hours after the rat
coronary artery occlusion-reperfusion, Cheng et al. [59]
transplanted retrovirus-mediated CXCR4-modiﬁed MSCs6 Stem Cells International
(CXCR4-MSCs)by intravenous injection. Results found that
the amount of CXCR4-MSCs’s homing in on the infarcted
myocardium was far more than that of the control group,
and 30 days after transplantation, cardiac function and ven-
tricular remodeling indicators gained the upper hand of the
MSCs or saline transplantation group.
7.4. Anti-Inﬂammatory. The nonspeciﬁc inﬂammation of
the body is one important reason that causes loss of trans-
planted cells [60] .T u m o rn e c r o s i sf a c t o r s( T N F )a r ea ni m -
portant kind of inﬂammatory mediators and act as a major
factor to the mediated apoptosis of the receptor. Bao et al.
[61] studied the anti-inﬂammatory and cardiac function
improvement eﬀects of TNF receptor- (TNFR-) modiﬁed
MSCs transplantation in the treatment of myocardial infarc-
tion. Two weeks after transplantation of TNFG-transfected
MSCs into the ischemic myocardium, they found that the
expression of inﬂammatory cytokines such as TNF-α,I L - 1 β,
and IL-6 reduced, myocardial apoptosis decreased and the
left ventricular function improved signiﬁcantly.
7.5. Multigene Modiﬁed MSCs Exploration. The ideal inter-
vention therapy for heart damage should at least include the
survival of transplanted cells and myocardial reperfusion.
The eﬀect of single gene is limited. Some researchers were
exploring a joint approach to meet diﬀerent demands of
therapy by applying to a variety of genes combination, and
they have made some achievements. Yau et al. [62]u s e d
MSCs which were transfected by VEGF and IGF-1 plasmid
to treat myocardial infarction. They found that the MSCs
with combined genes had the highest survival rate after one
week, while its improvement in cardiac function also showed
the best condition after 3 weeks. All suggest that multigene
combination therapy can play a therapeutic eﬀect of the
superposition. Some other studies have applied both Ang-
1 and Akt to modify MSCs transplantation cooperatively
to treat myocardial infarction to meet the demands of
angiogenesis and antiapoptosis. They also achieved the ex-
pected results. The cardiac function of rats has been further
improved, and having shown the long-term therapy eﬀects,
the results lasted for 3 months [63]. But the eﬀect of
mutigene transfection to biological behavior of stem cells is
not clear. Is there a single gene that can have both of the
functionsinthemeantime?SomeresearchersthinkthatHGF
has the ability in angiogenesis, anti-apoptosis, and promot-
ing cell migration, but there is still no acknowledged best
gene modiﬁcation program existing at present. The tissue
engineering research of genetic enhancement with MSCs as
the carrier has brought new hope to repair damaged hearts.
8.Conclusion
Although in some clinical trials stem cells have achieved
eﬀectiveness for ischemic heart disease, the eﬀectiveness of
stem cells is still lacking of consistency conclusion. Clinical
trials should try to unify stem cells separation, cultural
method, and transplantation approach, to set reasonable
control, and to have enough followup time. The design des-
tination should go beyond the alternative indicators, so as
to obtain suﬃcient convincing evidence to clarify the diﬀer-
ences in clinical endpoints, such as survival rate, hospitaliza-
tion rate, recurrent myocardial infarction. Stem cell trans-
plantation brings about hope, but the study of stem cell
therapy in cardiac repair is still in the initial stage. We
should be cautious about the study and application of
this technology. Improving the survival rate after stem cell
transplantation and prompt homing of stem cells may be
eﬀective strategies for stem cell therapy.
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